Qiagen companion diagnostic approved in Japan

Create PDF

March 2019—The Japanese Pharmaceuticals and Medical Device Agency has approved Qiagen’s Therascreen EGFR RGQ PCR Kit for use as a companion diagnostic with Pfizer’s Vizimpro (dacomitinib) for EGFR gene mutation-positive, inoperable or recurrent non-small cell lung cancer. This marks the first companion diagnostic approval for Qiagen in Japan. The kit is for use on the company’s Rotor-Gene Q MDx real-time PCR module.